Similarly, AI models are being used to predict response to ALK inhibitors in patients with ALK-positive NSCLC, potentially guiding treatment decisions and improving outcomes (142).Additionally, AI can integrate multidisciplinary data, encompassing genetic information, imaging data, clinical records, and lifestyle habits, to holistically evaluate patient health (143). Here, ALK is linked to non-small cell lung carcinoma.